Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
02
04
2020
revised:
16
04
2020
accepted:
23
04
2020
pubmed:
30
4
2020
medline:
19
6
2020
entrez:
30
4
2020
Statut:
ppublish
Résumé
The novel COVID-19 outbreak has affected more than 200 countries and territories as of March 2020. Given that patients with cancer are generally more vulnerable to infections, systematic analysis of diverse cohorts of patients with cancer affected by COVID-19 is needed. We performed a multicenter study including 105 patients with cancer and 536 age-matched noncancer patients confirmed with COVID-19. Our results showed COVID-19 patients with cancer had higher risks in all severe outcomes. Patients with hematologic cancer, lung cancer, or with metastatic cancer (stage IV) had the highest frequency of severe events. Patients with nonmetastatic cancer experienced similar frequencies of severe conditions to those observed in patients without cancer. Patients who received surgery had higher risks of having severe events, whereas patients who underwent only radiotherapy did not demonstrate significant differences in severe events when compared with patients without cancer. These findings indicate that patients with cancer appear more vulnerable to SARS-CoV-2 outbreak. SIGNIFICANCE: Because this is the first large cohort study on this topic, our report will provide much-needed information that will benefit patients with cancer globally. As such, we believe it is extremely important that our study be disseminated widely to alert clinicians and patients.
Identifiants
pubmed: 32345594
pii: 2159-8290.CD-20-0422
doi: 10.1158/2159-8290.CD-20-0422
pmc: PMC7309152
mid: NIHMS1589488
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
783-791Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL095489
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL131477
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM130668
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197697
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
©2020 American Association for Cancer Research.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cell Cycle. 2013 Sep 15;12(18):2978-91
pubmed: 23974111
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Lancet. 2014 Apr 26;383(9927):1503-1516
pubmed: 24290661
JAMA. 2020 Feb 24;:
pubmed: 32091533
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28
pubmed: 30678413
Lancet. 2009 Jul 25;374(9686):324-39
pubmed: 19541364
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Nat Rev Immunol. 2018 Mar;18(3):195-203
pubmed: 29332937
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28544595
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet. 2003 May 24;361(9371):1773-8
pubmed: 12781536
Int J Mol Sci. 2018 Apr 20;19(4):
pubmed: 29677173
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632